In an unscripted moment of synchronicity, the complete response letter for linvoseltamab announced by Regeneron Pharmaceuticals, Inc. on 20 August exemplified the findings of a US Food and Drug Administration analysis of biologics approvals presented to a Duke-Margolis Institute for Health Policy meeting the same day.
Key Takeaways
-
The FDA’s complete response for Regeneron’s linvoseltamab rests on findings from an inspection for another company’s candidate that uses the same third-party manufacturer, echoing previous CRLs for Checkpoint’s cosibelimab and Lilly’s lebrikizumab
Regeneron said the linvoseltamab CRL listed one approvability issue related to “findings from a pre-approval inspection at a third-party fill/finish
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?